Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Peringkat dalam Saham #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Harga Saham
$8.74
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$699.74M
Perubahan (1 hari)
-4.85%
Perubahan (1 tahun)
-2.29%
Negara
US
Perdagangan BridgeBio Oncology Therapeutics Inc. (BBOT)

Kategori

Rasio P/S untuk BridgeBio Oncology Therapeutics Inc. (BBOT)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari BridgeBio Oncology Therapeutics Inc., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk BridgeBio Oncology Therapeutics Inc. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH